Navigation Links
HumanZyme® Announces Human Cell-Expressed Interferon gamma for Immunology and Immunotherapy Research Applications
Date:9/26/2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma, also known as Type II interferon, protects against bacterial, viral and protozoan infections, and is produced by TH-1 or NK cells. Important research is underway on the immunomodulatory activity of IFN gamma, including stimulation of cell-based immunity and cytotoxicity. IFN gamma has been evaluated for use in a variety of clinical applications including as an anti-cancer biotherapeutic, and is FDA approved for the treatment chronic granulomatous disease (CGD) and severe, malignant osteoporosis.

According to Scott Coleridge, CEO at HumanZyme, “Recombinant human IFN-beta is the latest offering in a series of new, high-quality, HEK293-expressed cytokines that are difficult to manufacture. Using our proprietary HEK293 expression system, we are proud to be one of only a few commercial suppliers to offer tag-free recombinant human Interferon gamma expressed in human cells for research purposes. The new IFN gamma further expands our recombinant human interferon product offering to include IFN alpha 2a, IFN alpha 2b, IFN beta, and now IFN gamma.”

IFN gamma has two N-linked glycosylation sites, Asn-25 and Asn-97, on the surface of the dimer, and glycosylation is essential to its half-life in human serum and its full biological activity. Producing IFN gamma in HEK293 cells assures native human processing, glycosylation and folding of the purified protein compared to non-human bacterial and mammalian cell lines, or insect cell expression systems. HumanZyme’s HumanKine proteins are high quality, are animal-derived product free, xeno-free and carrier-free, and are available in bulk.

For more information, see our Interferon gamma product page.

About HumanZyme, Inc.
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14736027.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. HumanZyme® Launches New XKine™ Recombinant Protein Line Expanding Reagents For Stem Cell Research and Regenerative Medicine Applications
2. HumanZyme® Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research Applications
3. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
4. Annual Conference about Technology Solutions for People with Disabilities Announces Program
5. Probiotic Action Announces Probiotics Lead the Digestive Health Market
6. Verenium Announces Preliminary Financial Results For Fiscal 2012
7. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
8. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
9. EAG Announces New General Manager of Release-To-Production (RTP) Division
10. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
11. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... 08, 2019 , ... VGI Medical was founded in 2007 based on an ... to the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems ... patented dual geometric design to limit motion of the affected spinal segment. Applying the ...
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today announced ... candidate, code-named "KM-819." KM-819 is an orally active small molecule that is ... Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to ...
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life , ... in blood, has been named as a partner in Medigen Biotech’s upcoming cell ... therapies for cancer treatment, will use CellMax Life’s circulating tumor cell platform CMxTM, ...
(Date:12/19/2018)... ... December 19, 2018 , ... R3 Stem ... Stem Cell Training Course in Las Vegas. Training includes facial rejuvenation, hair restoration ... in popularity nationwide for aesthetics, having the training from expert, Board Certified providers ...
Breaking Biology Technology:
(Date:12/19/2018)... ... December 19, 2018 , ... InTouchMD’s flagship product, Pulse ... healthcare for 2018. , PM360 is featuring the recognition in its 7th annual ... services offered to the pharmaceutical and medical device industries. , “This recognition comes at ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US ... October 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary ...
(Date:12/13/2018)... LAKELAND, Fla. (PRWEB) , ... December 12, 2018 , ... ... and preventing the growing problem of drowsy and distracted driving, one of the main ... project, under the guidance of Dr. Kanwal Gagneja , assistant professor of computer ...
Breaking Biology News(10 mins):